Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide.
about
Virulence factors of medically important fungiCryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.Concomitant but not causal association between surface charge and inhibition of phagocytosis by cryptococcal polysaccharide.Phenoloxidase activity and virulence in isogenic strains of Cryptococcus neoformans.Cyclic AMP-dependent protein kinase controls virulence of the fungal pathogen Cryptococcus neoformansThe capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibodyIntracellular crystal formation as a mechanism of cytotoxicity in murine pulmonary Cryptococcus neoformans infectionOpsonization of Cryptococcus neoformans by human immunoglobulin G: role of immunoglobulin G in phagocytosis by macrophages.Opsonization of Cryptococcus neoformans by human immunoglobulin G: masking of immunoglobulin G by cryptococcal polysaccharide.Chemotaxigenesis and activation of the alternative complement pathway by encapsulated and non-encapsulated Cryptococcus neoformansPrimary dendritic cells phagocytose Cryptococcus neoformans via mannose receptors and Fcgamma receptor II for presentation to T lymphocytesImmune response to Cryptococcus neoformans soluble polysaccharide: immunological unresponsivenessNon-encapsulated variant of Cryptococcus neoformans. II. Surface receptors for cryptococcal polysaccharide and their role in inhibition of phagocytosis by polysaccharideCapsule size of Cryptococcus neoformans: control and relationship to virulence.Phagocytosis of Cryptococcus neoformans by normal and thioglycolate-activated macrophagesImmune response to Cryptococcus neoformans soluble polysaccharide. I. Serological assay for antigen and antibodySusceptibility of melanized and nonmelanized Cryptococcus neoformans to nitrogen- and oxygen-derived oxidants.Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxideGenetic study of oxygen resistance and melanization in Cryptococcus neoformans.Extracellular glycoprotein from virulent and avirulent Cryptococcus species.Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1 beta secretion from human monocytesStructure and biological activities of acapsular Cryptococcus neoformans 602 complemented with the CAP64 geneSecretion of the C3 component of complement by peritoneal cells cultured with encapsulated Cryptococcus neoformans.Identification of a Cryptococcus neoformans gene that directs expression of the cryptic Saccharomyces cerevisiae mannitol dehydrogenase gene.Role of phagocytosis in the virulence of Cryptococcus neoformans.The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies.Recombinational mapping of capsule mutations in Cryptococcus neoformansGenetic and phenotypic characterization of capsule mutants of Cryptococcus neoformans.Auxotrophic mutants of Cryptococcus neoformans.Dissociation of a hydrophobic surface from phagocytosis of encapsulated and non-encapsulated cryptococcus neoformans.Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization.UDP glucuronate decarboxylase and synthesis of capsular polysaccharide in Cryptococcus neoformans.Immediate hypersensitivity to Cryptococcus neoformansOpsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody.Cryptococcus neoformans Rim101 is associated with cell wall remodeling and evasion of the host immune responses.Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence.The glucuronoxylomannan of Cryptococcus neoformans serotype A is a type 2 T-cell-independent antigenGalactoxylomannans of Cryptococcus neoformans.Killing of Cryptococcus neoformans strains by human neutrophils and monocytes.
P2860
Q24683790-528D0172-0991-4F83-B34E-0DF7235BA9D0Q30424017-67DDD1D1-A1B3-4895-BB74-9DD555C7B73CQ33751411-926995D7-C02C-459A-A60D-9F445FA3CEF8Q33905575-FCA47910-6F05-4554-B3CF-5A7B31FE7D44Q33913191-C3A87D5C-A055-4EE9-8D31-807827DA6394Q33968048-A6D90586-1965-4C3B-B0DE-6039C88EA23DQ34001769-E3154EFA-524F-4A7C-A532-F0E4E3D0D9CFQ34007067-07BED296-1827-4280-AD3E-A65AD1EC1C6BQ34088603-A4B88A2A-5377-4DDB-BBC5-8710B8E2A0B6Q34088651-3B03796A-C985-43EA-BCD4-92D20EDE2144Q34096432-59F9BDD2-4021-497A-9325-51281657AA32Q34182880-1F1DE5DE-78DF-414E-ABE2-89EF224C6CAFQ34420549-3F39AD4F-F58D-480E-91D4-CCB6F019F613Q34429542-F7B98AA5-A100-4871-92A2-F61C287A8032Q34429758-27D8652A-E6F9-4A9E-A68A-93ED04A85C73Q34454156-D14C3F40-8099-4DE0-8A98-CADDC06B679EQ34466900-F02AF1CF-DAF1-4D32-A143-957ACC82A4A7Q34530881-1C33ADC8-C364-4751-B82F-E91685A4BA73Q34547882-93AE85CB-BD3E-4424-A096-F8AE523B3AD1Q34549734-43968476-D04B-4DAD-959F-7FE742594658Q34716807-059C3B5B-8C9A-4DDD-9F18-150D36BBB60AQ35427625-BDCC3A0E-EA91-4745-882D-C2E65AFF9F65Q35546019-ACAFCF24-65A6-4543-8D21-616773C3551EQ35556339-EAE2DA32-C5A5-4ED3-BD77-077477E6D757Q35611936-F8EEF644-9191-4E86-8DB2-0A51DAB4D973Q35911335-2768E753-3F9A-406B-84A8-135F29EACE5CQ36230201-875C458A-721D-474A-AEC2-CDEBF0686888Q36294648-CCEA7E9B-FF3D-403C-A171-18106D5DD608Q36309618-699017B2-D6F6-49BB-AB43-3A050D152B6FQ36314721-11EE4442-1E08-4F92-8EBC-8CC5AA177A7BQ36346286-39B62D1F-80E6-473F-8CA9-AFF9AB1FCD12Q36361541-40E8FD3A-944E-43C7-BCB5-25ABB8DC7468Q36408691-37ED7545-328B-481B-B60A-B5555D870610Q36443790-94300E28-4065-49B5-8579-A6BD0150F703Q36444623-70D35410-FD2C-4555-A3CC-AF184ADE5294Q36551864-8A768874-A46D-41DC-B380-1E35AFD73911Q36657718-F969821B-3578-4A47-BB83-45BE940C1880Q36951576-0B941074-1801-4097-8058-67BD5B585FF1Q36956261-864F330A-A9AD-4C5B-A330-A8616A81B051Q36958548-E786A67B-0410-4325-A02B-9DCDA714ED98
P2860
Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide.
description
1971 nî lūn-bûn
@nan
1971 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1971 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1971年の論文
@ja
1971年論文
@yue
1971年論文
@zh-hant
1971年論文
@zh-hk
1971年論文
@zh-mo
1971年論文
@zh-tw
1971年论文
@wuu
name
Nonencapsulated Variant of Cry ...... ion of Soluble Polysaccharide.
@ast
Nonencapsulated Variant of Cry ...... ion of Soluble Polysaccharide.
@en
Nonencapsulated Variant of Cry ...... ion of Soluble Polysaccharide.
@nl
type
label
Nonencapsulated Variant of Cry ...... ion of Soluble Polysaccharide.
@ast
Nonencapsulated Variant of Cry ...... ion of Soluble Polysaccharide.
@en
Nonencapsulated Variant of Cry ...... ion of Soluble Polysaccharide.
@nl
prefLabel
Nonencapsulated Variant of Cry ...... ion of Soluble Polysaccharide.
@ast
Nonencapsulated Variant of Cry ...... ion of Soluble Polysaccharide.
@en
Nonencapsulated Variant of Cry ...... ion of Soluble Polysaccharide.
@nl
P2860
P1476
Nonencapsulated Variant of Cry ...... tion of Soluble Polysaccharide
@en
P2093
P2860
P304
P407
P577
1971-02-01T00:00:00Z